Department of Family Medicine, University of Arkansas for Medical Sciences, 4301 W. Markham St., Little Rock, AR 72205, USA.
Osteoporos Int. 2013 Apr;24(4):1333-8. doi: 10.1007/s00198-012-2109-4. Epub 2012 Aug 18.
Increased incidence of osteoporosis in Down syndrome has been reported, but etiology is not established. We report low bone turnover markers and bone mineral density (BMD) in a cohort of people with Down syndrome without consistent clinical risk factors. Our results should guide future studies and treatments for this common problem.
To better understand the etiology for osteoporosis in Down syndrome (DS), we measured bone density by dual-energy X-ray absorptiometry (DXA) and circulating biochemical markers of bone formation and resorption in a cohort of 30 community-dwelling DS adults.
Seventeen males and 13 females followed in the University of Arkansas Down Syndrome Clinic were evaluated by DXA to estimate BMD and underwent phlebotomy to measure serum procollagen type-1 intact N-terminal propeptide (P1NP) to evaluate bone formation, and serum C-terminal peptide of type-I collagen (CTx) to evaluate bone resorption.
Seven of 13 DS females and 12 of 17 DS males had low bone mass at one of measured sites (z≤-2.0). When data were grouped by age, males had apparent osteopenia earlier than females. The mean P1NP in the normal group was 19.2±5.2 ng/ml vs. 2.2±0.9 ng/ml in the DS group (P=0.002). Serum CTx levels in the normal group were 0.4±0.1 ng/ml vs. 0.3±0.1 ng/ml (P=0.369).
Low BMD in adults with DS is correlated with a significant decrease in bone formation markers, compared to controls without DS, and is independent of gender. These data suggest that diminished osteoblastic bone formation and inadequate accrual of bone mass, with no significant differences in bone resorption, are responsible for the low bone mass in DS. These observations question the use of antiresorptive therapy in this population and focus attention on increasing bone mass by other interventions.
为了更好地了解唐氏综合征(DS)患者骨质疏松症的病因,我们通过双能 X 射线吸收法(DXA)测量了一群居住在社区的 DS 成年患者的骨密度,并检测了循环骨形成和骨吸收的生化标志物。
我们评估了在阿肯色大学唐氏综合征诊所随访的 30 名 DS 成人患者的 DXA,以估计骨密度,并进行了静脉采血以测量血清Ⅰ型前胶原氨基端肽(P1NP)以评估骨形成,以及血清Ⅰ型胶原 C 端肽(CTX)以评估骨吸收。
13 名 DS 女性中有 7 名和 17 名 DS 男性中有 12 名在一个测量部位的骨密度较低(z≤-2.0)。当按年龄分组时,男性比女性更早出现骨质疏松症。正常组的平均 P1NP 为 19.2±5.2ng/ml,DS 组为 2.2±0.9ng/ml(P=0.002)。正常组的血清 CTx 水平为 0.4±0.1ng/ml,DS 组为 0.3±0.1ng/ml(P=0.369)。
与无 DS 的对照组相比,DS 成人的低骨密度与骨形成标志物显著降低相关,且与性别无关。这些数据表明,破骨细胞骨形成减少和骨量积累不足导致了 DS 中的低骨量,而骨吸收无显著差异。这些观察结果质疑了在该人群中使用抗吸收治疗的方法,并将注意力集中在通过其他干预措施增加骨量上。